Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
174
resultados
Última actualización
17/09/2025 [07:45:00]
Resultados 75 a 100 de 174
Resumen de: WO2025136105A1
The invention relates to methods of predicting a response of an individual suffering from an inflammatory bowel diseases, such as Crohn's disease (CD) to treatment with a Tumor Necrosis Factor alpha inhibitor (TNFα-i). The invention further relates to anti-TNFα therapy, for treating an individual who was predicted to positively respond to said therapy by the methods of the invention, and to an integrin α4β7 blocking agent, or interleukin (IL)-12 and IL-23 blocking agent, for treating an individual who was predicted not to respond to anti-TNFα therapy by the methods of the invention.
Resumen de: CN120195385A
The invention belongs to the technical field of biomedicine, and particularly relates to application of xylulose-5-phosphoric acid as an inflammatory bowel disease biomarker with intestinal fibrosis characteristics. It is found for the first time that xylulose-5-phosphoric acid is remarkably increased in a biological sample of a patient with the inflammatory bowel disease with the intestinal fibrosis characteristic, and the expression level of xylulose-5-phosphoric acid in the biological sample of the patient with the inflammatory bowel disease with the intestinal fibrosis characteristic is in a positive correlation relation with the occurrence degree of the intestinal fibrosis. The discovery provides an important therapeutic target for predicting or evaluating whether a subject suffers from the inflammatory bowel disease with the intestinal fibrosis characteristic by using the xylulose-5-phosphoric acid as the inflammatory bowel disease biomarker with the intestinal fibrosis characteristic.
Resumen de: CN120198599A
The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.
Resumen de: CN120174078A
The invention provides a composition for diagnosing Crohn's disease, a kit and application of an enhancer RNA44345 in preparation of the composition, and relates to the technical field of biological medicines. The invention relates to an application of an enhancer RNA44345 in preparation of a composition for diagnosing Crohn's disease, and the enhancer RNA44345 is used as a detection marker of the composition for diagnosing Crohn's disease. The enhancer RNA44345 serves as a detection marker of the composition for diagnosing the Crohn disease, the sensitivity is 74.6%, the specificity is 81.7%, the sensitivity and the specificity are high, and a new tool can be provided for early diagnosis and prognosis evaluation of the Crohn disease.
Resumen de: WO2025128818A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Resumen de: US2025197388A1
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.
Resumen de: NZ730490A
Described herein are methods and systems for distinguishing diarrhea predominant irritable bowel syndrome (D-IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: CN120164631A
The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.
Resumen de: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Resumen de: CN120142669A
The invention discloses a serum protein and metabolism marker for diagnosis or auxiliary diagnosis of colorectal cancer or ulcerative colitis, the serum protein and metabolism marker comprises 10 serum protein markers or/and 11 serum metabolites, the serum protein markers comprise APOA4, APOC3, APOF, C4B, CLEC3B, FERMT3, NID2, RAB11B, CRP and CSF1, and the serum metabolism markers comprise LysoPA 18: 2, LysoPA 18: 3, Valproic acid, LysoPA 16: 0, Cis-4-DGTS 12: 0, Choline, Acylcarnitine 19: 3 and Cis-4-. By screening differentially expressed serum proteins and metabolites of patients with colorectal cancer and ulcerative colitis, machine learning is utilized to screen markers and construct a diagnosis model, so that diagnosis and auxiliary diagnosis of colorectal cancer are facilitated. In addition, the invention further discloses application of the serum protein and the metabolic marker, and the serum protein marker and the serum metabolic marker are used independently or in a combined mode.
Resumen de: CN120138126A
The invention relates to the technical field of disease detection kits, in particular to application of an scrK gene as a target spot to preparation of a kit or a medicine for detecting or treating enteritis related to abnormal fructose metabolism. The detection of the abnormal fructose metabolism related enteritis comprises the following steps: detecting the expression level of an scrK gene of a sample to be detected, and judging whether the source of the sample to be detected has abnormal fructose metabolism related enteritis (such as inflammatory bowel disease) or not according to a detection result and the fructose content, or judging the severity of the enteritis related to abnormal fructose metabolism from the sample to be detected. A target spot (scrK gene) of enteritis related to abnormal fructose metabolism is found through research, a plurality of detection kits applied to abnormal fructose metabolism diseases such as inflammatory bowel diseases and intestinal inflammation-cancer transformation process can be developed based on detection of the gene, the cause of occurrence or aggravation of enteritis is defined, and the application prospect is wide. And direct evidence is provided for accurate diagnosis and treatment.
Resumen de: CN120138155A
The invention discloses a method for analyzing and identifying an inflammatory bowel disease related oral cancer biomarker, and belongs to the technical field of bioengineering.The method comprises the following steps that 1, IBD whole genome correlation research summary data is obtained; 2, analyzing a causal relationship between IBD and the oral cancer by using a Mendel randomization method, and determining IBD related genes; 3, collecting an oral cancer tissue sample, and carrying out single-cell RNA sequencing; according to the invention, single-cell RNA sequencing is carried out on an oral cancer specimen, and a cell cluster and a gene expression mode are described. Cell clusters and types are displayed by using t-SNE and UMAP, key modes of gene expression are defined by using a lattice diagram, and pathways related to NFKBIA expression are analyzed through GSEA. The experimental result explains the cell heterogeneity and gene expression kinetics in the oral cancer disease progression process, and reveals possible therapeutic targets related to IBD.
Resumen de: CN120138119A
The invention provides a method for evaluating the intervention effect of probiotics based on baseline intestinal microbiome robustness, which comprises the following steps: collecting a sample of a mouse colitis model for metagenome sequencing, analyzing the robustness of the intestinal microbiome of an individual in a baseline period, and evaluating the intervention effect of the probiotics, the mouse colitis model comprises a control group, a model group and a probiotic group. Experimental results show that based on the robustness of the host baseline microbiome, the curative effect of the probiotic intervention treatment on the IBD can be more accurately deduced. The prediction effect of the robustness of the intestinal microorganisms in the baseline period on probiotic treatment is elaborated, and a theoretical basis and technical support are provided for optimizing a probiotic treatment scheme in clinical practice.
Resumen de: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Resumen de: US2025191684A1
Example embodiments relate to identity-by-descent (IBD) relatedness based on focal and reference segments. An example method includes determining, by a services platform based on personal information of a focal individual, a focal string. The method also includes retrieving, by the services platform from a reference database, a reference string of a reference individual. Additionally, the method includes computationally identifying, by the services platform, IBD segments between the focal string and the reference string. Further, the method includes determining, by the services platform and based on the merged set of IBD segments, a degree of relatedness between the focal individual and the reference individual. In addition, the method includes providing, by the services platform, access to the degree of relatedness via a user interface.
Resumen de: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Resumen de: CN120129835A
Provided are: a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12 in a subject; a diagnostic reagent containing a substance that specifically interacts with MMP12; and a therapeutic agent containing a substance that inhibits MMP12.
Resumen de: CN113645846A
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: CN120107161A
The invention discloses an intestinal lymphoma and Crohn disease identification model construction method and system, and the method comprises the following steps: S1, selecting endoscopic images of an intestinal lymphoma patient and a Crohn disease patient from a hospital, and respectively applying the endoscopic images to an internal verification experiment and an external verification experiment; s2, preprocessing the image through an image mask algorithm and a data enhancement technology; s3, constructing and training an InceptionV3 convolutional neural network model, selecting an optimal hyper-parameter combination through internal verification, and then performing external verification to determine the classification efficiency of the model; and S4, performing statistical analysis on the diagnosis result of the clinician. The InceptionV3 model constructed by adopting the method not only has efficient diagnosis performance which is obviously superior to a primary endoscopic physician and equivalent to a high-grade endoscopic expert, but also remarkably improves the endoscopic diagnosis rate of the primary clinical physician, and provides powerful support for primary medical institutions and medical centers lacking experience.
Resumen de: US2020262889A1
Polypeptides comprising an amino acid sequence of Slc26a6 or IRBIT comprising a mutation that increases NaDC-1 binding, stability of the polypeptide, stability of NaDC-1 complex or a combination thereof are provided. Polypeptides comprising an amino acid sequence of a mutant succinate receptor 1 (mutSUCNR1), comprising a mutation that increases succinate binding, stability of the polypeptide, stability of the mutSUCNR1-succinate complex or combinations thereof are also provided. Compositions comprising the polypeptides, nucleic acid molecules and vectors encoding the polypeptides, and methods of use of the polypeptides or compositions, specifically for treating succinate-associate diseases and conditions are also provided.
Resumen de: WO2025117950A1
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Resumen de: US2025177779A1
In some embodiments, the present disclosure relates to a method. The method includes extracting a plurality of pre-treatment features from one or more first regions of interest (ROI) within pre-treatment imaging data. Prognostic pre-treatment features are identified from the plurality of pre-treatment features. The prognostic pre-treatment features are determinative of a treatment response. A plurality of post-treatment features are extracted from one or more second ROI within post-treatment imaging data. Prognostic post-treatment features are extracted from the plurality of post-treatment features. The prognostic post-treatment features are determinative of the treatment response. Prognostic tumor diversity features are determined from a common subset of the prognostic pre-treatment features and the prognostic post-treatment features. A machine learning stage is operated to generate a medical prediction of the treatment response for a bowel cancer patient using the prognostic tumor diversity features.
Resumen de: US2025180579A1
Methods for identifying sensitivity to what in an individual are provided, in which a sample from the individual is characterized for the presence of antibodies reactive with a whole wheat antigen and differentially characterizes for antibodies reactive with transglutaminase-2, transglutaminase-3, and transglutaminase-6. The presence of antibodies reactive with other wheat antigens, including α-gliadin, native γ-gliadin, native {acute over (ω)}-gliadin, and glutenin can also be characterized.
Resumen de: WO2025114553A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.The present invention also refers to an in vitro method for monitoring patients suffering from a chronic inflammatory disease selected from the group comprising: IBD, arthritis or psoriasis; and/or for differentiating active patients suffering from a chronic inflammatory disease selected from the group comprising: IBD, arthritis or psoriasis from those patients who are in remission.
Nº publicación: EP4564005A1 04/06/2025
Solicitante:
AIRBIOMETRICS ADVANCED SOLUTIONS SL [ES]
Airbiometrics Advanced Solutions SL
Resumen de: EP4564005A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.
BOPI
Sede Electrónica
